Overview

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist with FDA approval for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023).

Mechanism of Action

Dual incretin agonism — Activates both GIP and GLP-1 receptors
Superior weight loss — Dual action produces greater weight loss than GLP-1 alone
Glucose control — Potent HbA1c reduction
Appetite suppression — Central and peripheral satiety signaling

Dosing Protocols

| Week | Dose | Frequency | |------|------|-----------| | 1-4 | 2.5mg | Once weekly | | 5-8 | 5mg | Once weekly | | 9-12 | 7.5mg | Once weekly | | 13-16 | 10mg | Once weekly | | 17-20 | 12.5mg | Once weekly | | 21+ | 15mg | Once weekly (maintenance) |

Safety Profile

FDA-approved. Most common adverse effects: nausea, diarrhea, vomiting, constipation, abdominal pain. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2.